Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to tr... Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease. Show more
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, Sept. 23, 2024 SAN DIEGO, Sept. 23, 2024 /PRNewswire/ --Β Avidity Biosciences, Inc...
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month PR Newswire SAN DIEGO, Sept. 5, 2024 Avidity supports World...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.4 | 3.32541567696 | 42.1 | 46.0892 | 41.69 | 3384514 | 44.44509178 | CS |
4 | -0.26 | -0.594149908592 | 43.76 | 46.0892 | 39.3509 | 1563425 | 43.24764055 | CS |
12 | 2.22 | 5.37790697674 | 41.28 | 48.8012 | 36.63 | 1421346 | 43.74897532 | CS |
26 | 19.87 | 84.0880236987 | 23.63 | 48.8012 | 21.56 | 1374454 | 37.16381362 | CS |
52 | 37.08 | 577.570093458 | 6.42 | 48.8012 | 4.825 | 1305162 | 24.8580042 | CS |
156 | 19.49 | 81.1745106206 | 24.01 | 48.8012 | 4.825 | 945334 | 20.00904827 | CS |
260 | 17 | 64.1509433962 | 26.5 | 48.8012 | 4.825 | 746010 | 20.631498 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.